Kiem Sungmin, Schentag Jerome J
Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
School of Pharmacy and Pharmaceutical Sciences, The University at Buffalo, Buffalo, NY, USA.
Infect Chemother. 2013 Sep;45(3):283-91. doi: 10.3947/ic.2013.45.3.283. Epub 2013 Sep 27.
In treatment of pneumonia, microorganisms sometimes persist, appear or reappear despite good clinical responses. On the other hand, recent increasing antibiotic resistance emphases the goal of rapid eradication of pathogen in severe infection. This study was planned to evaluate the correlations between microbiological outcomes and clinical responses in severe pneumonia.
Data was gathered from 3 clinical trials regarding severe pneumonia. Microbiological outcomes, determined by serial culture of respiratory tract samples,were compared with clinical outcomes.
In total, 146 bacterial strains from 76 patients were analyzed. While clinical success was generally related to total or partial eradication of isolated organisms, Acinetobacter, Enterobacter, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia were often not eradicated and yet were observed in 56% of cases considered clinically successful at the end of antibiotic treatment. Most of the non-eradicated strains (71%) already had or developed resistance against the antibiotics used for treatment. Ten patients relapsed during the follow-up period; 7 of these relapses were associated with 10 non-eradicated organisms.
These data raise concern about the pathogenicity of bacteria that persist in the respiratory tract even though good clinical outcomes of pneumonia are achieved, especially when Acinetobacter, Enterobacter, P. aeruginosa, or S. maltophilia were involved. Thus, clinical relapse and development of drug resistance by non-eradicated organisms may be raised.
在肺炎治疗中,尽管临床反应良好,但微生物有时仍会持续存在、出现或再次出现。另一方面,近期抗生素耐药性的增加凸显了在严重感染中快速根除病原体的目标。本研究旨在评估重症肺炎微生物学结果与临床反应之间的相关性。
收集了3项关于重症肺炎的临床试验数据。通过呼吸道样本的系列培养确定的微生物学结果与临床结果进行了比较。
共分析了76例患者的146株细菌菌株。虽然临床成功通常与分离出的生物体的全部或部分根除有关,但不动杆菌、肠杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌通常未被根除,然而在抗生素治疗结束时被认为临床成功的病例中,有56%观察到了这些细菌。大多数未被根除的菌株(71%)已经对或产生了对用于治疗的抗生素的耐药性。10名患者在随访期间复发;其中7例复发与10株未被根除的生物体有关。
这些数据引发了人们对即使肺炎临床结果良好但仍在呼吸道中持续存在的细菌的致病性的关注,尤其是当涉及不动杆菌、肠杆菌、铜绿假单胞菌或嗜麦芽窄食单胞菌时。因此,可能会出现临床复发和未被根除的生物体产生耐药性的情况。